Bionano Genomics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.2M | $6.7M | $8.0M | $7.4M | $6.7M | $6.5M | $8.2M | $6.1M |
| Cost of Revenue | $3.9M | $3.4M | $4.6M | $4.0M | $3.3M | $3.5M | $4.7M | $14.5M |
| Gross Profit | $4.3M | $3.3M | $3.4M | $3.4M | $3.5M | $2.9M | $3.4M | $-8.4M |
| Gross Margin | 52.8% | 48.6% | 42.8% | 45.7% | 51.6% | 45.5% | 41.9% | -139.1% |
| Operating Expenses | ||||||||
| Research & Development | $3.0M | $3.1M | $3.2M | $2.8M | $2.9M | $2.4M | $3.5M | $4.7M |
| SG&A Expense | $8.5M | $8.0M | $8.7M | $9.1M | $8.3M | $9.0M | $11.7M | $9.5M |
| Operating Income | $-7.2M | $-7.9M | $-8.5M | $-8.5M | $-7.8M | $-8.5M | $-11.9M | $-43.9M |
| Operating Margin | -88.3% | -118.1% | -107.4% | -115.9% | -115.8% | -131.1% | -146.3% | -722.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-7.4M | $-8.3M | $-7.9M | $-8.5M | $-6.8M | $-3.1M | $-20.1M | $-44.2M |
| Income Tax Expense | $7.0K | $10.0K | $36.0K | $14.0K | $10.0K | $7.0K | $1.0K | $24.0K |
| Net Income | $-7.4M | $-8.3M | $-7.9M | $-8.5M | $-6.9M | $-3.1M | $-20.1M | $-44.2M |
| Net Margin | -90.8% | -124.2% | -99.8% | -115.4% | -101.8% | -48.0% | -246.5% | -728.6% |
| EPS (Basic) | $-0.64 | $-0.76 | $-0.12 | $-0.40 | $-0.50 | $-0.29 | $-1.76 | $-3.87 |
| EPS (Diluted) | $-0.64 | $-0.76 | $-0.12 | $-0.40 | $-0.50 | $-0.29 | $-1.76 | $-3.87 |
| Shares Outstanding (Basic) | 11.5M | 11.0M | 5.4M | 21.4M | 13.8M | 10.8M | 5.1M | 11.4M |
| Shares Outstanding (Diluted) | 11.5M | 11.0M | 5.4M | 21.4M | 13.8M | 10.8M | 5.1M | 11.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |